1 n 24 h of AHF presentation in a prospective,
double blind, placebo-controlled trial.
2 This was a
double-blind, placebo-controlled trial.
3 dystrophinopathy, we conducted a randomized,
double-blind, placebo-controlled trial.
4 (teriparatide) or placebo for 18 months in a
double-blind, placebo-controlled trial.
5 e cancer were enrolled into a multinational,
double-blind, placebo-controlled trial.
6 abdominis plane (TAP) block in a randomized,
double-blind, placebo-controlled trial.
7 pated in the 2-year prospective, randomized,
double-blind, placebo-controlled trial.
8 en allergic to grass pollen in a randomized,
double-blind, placebo-controlled trial.
9 pendent outpatients in a 10-week randomized,
double-blind, placebo-controlled trial.
10 We conducted a single-center, randomized,
double-blind, placebo-controlled trial.
11 ients were enrolled in a 2-year, randomized,
double-blind, placebo-controlled trial.
12 ght and obesity.This study was a randomized,
double-blind, placebo-controlled trial.
13 doxycyline in a pre-registered, randomised,
double-blind, placebo-controlled trial.
14 nse to anifrolumab may be examined in larger
double-blind, placebo-controlled trials.
15 rder (BED) was evaluated in two multicenter,
double-blind, placebo-controlled trials.
16 We did two randomised,
double-blind, placebo-controlled trials.
17 ertiary HPS unit were randomly assigned in a
double-blinded, placebo-controlled trial.
18 a variable degree of efficacy in randomized,
double-blinded, placebo-controlled trials.
19 In a pilot randomized,
double-blind, placebo-controlled trial,
100 mg of DCS or
20 In this
double-blind, placebo-controlled trial,
120 asymptomatic
21 In this randomized,
double-blind, placebo-controlled trial,
18- to 50-year-o
22 In a randomised
double-blind, placebo controlled trial,
22 early onset P
23 In this randomized,
double-blind, placebo-controlled trial,
26 adult patient
24 In this single-centre, randomised,
double blind, placebo-controlled trial,
31 patients with
25 In a randomised,
double-blind, placebo-controlled trial,
40 HIV-infected
26 In this 2 x 2 factorial,
double-blind placebo-controlled trial,
457 lead-exposed
27 In this randomized,
double-blind, placebo-controlled trial,
50 patients with
28 In this randomized,
double-blind, placebo-controlled trial,
94 preterm infan
29 n this prospective, multicenter, randomized,
double-blind, placebo-controlled trial,
96 HT recipients
30 In this
double-blind, placebo-controlled trial,
adolescents 12 t
31 In this single-centre, randomised,
double-blind, placebo-controlled trial,
adult patients (
32 For this international, multicentre,
double-blind, placebo-controlled trial,
adult patients (
33 In this multicentre, randomised,
double-blind, placebo-controlled trial,
adults (>/=18 ye
34 In this randomised,
double-blind, placebo-controlled trial,
adults with pred
35 incidence of herpes zoster in a randomized,
double-blind, placebo-controlled trial among 3408 person
36 We conducted a 2-year, randomized,
double-blinded, placebo-controlled trial among 2727 hous
37 ther well-designed and statistically powered
double-blind, placebo-controlled trials are needed.
38 This exploratory, randomized,
double-blind, placebo-controlled trial assessed a preemp
39 This randomized,
double-blind, placebo-controlled trial assessed the effe
40 In this phase 3, multicentre,
double-blind, placebo-controlled trial at 104 sites in E
41 In this randomised,
double-blind, placebo-controlled trial at 590 sites in 4
42 We undertook a multicentre,
double-blind, placebo-controlled trial at 81 centres in
43 We did a single-centre,
double-blind, placebo-controlled trial at the Glasgow Cl
44 We did a randomised,
double-blind, placebo-controlled trial at three centres
45 Double-blinded, placebo-controlled trial at 9 academic m
46 We did this randomised,
double-blind, placebo-controlled trial between Dec 15, 2
47 In this randomised,
double-blind, placebo-controlled trial,
boys from three
48 We performed our study as a randomized,
double-blind, placebo-controlled trial by training other
49 NG, AND PATIENTS: Two replicate, randomized,
double-blind, placebo-controlled trials (
C0405 and C0406
50 In this multicentre, randomised, parallel,
double-blind, placebo-controlled trial,
children aged 4-
51 This multicenter,
double-blind, placebo-controlled trial compared the effe
52 ual Antiplatelet Therapy Study, a randomized
double-blind, placebo-controlled trial,
compared 30 vers
53 METHODS AND TIME was a randomized,
double-blind, placebo-controlled trial comparing 150 mil
54 International, multicenter, randomized,
double-blinded, placebo-controlled trial comparing exten
55 of asthma, were included in the randomized,
double-blind, placebo-controlled trial,
comprising 3 yea
56 f the evidence varies considerably, with few
double-blind placebo-controlled trials conducted.
57 DESIGN, SETTING, AND PATIENTS: Randomized,
double-blind, placebo-controlled trial conducted among 2
58 SIGN, SETTING, AND PARTICIPANTS: Randomized,
double-blind, placebo-controlled trial conducted among 3
59 (SNPs) in 2259 participants in a randomized,
double-blind, placebo-controlled trial conducted at 11 c
60 Phase 3, randomized,
double-blind, placebo-controlled trial conducted at 18 s
61 IGN, SETTING, AND PARTICIPANTS: Multicenter,
double-blind, placebo-controlled trial conducted at 4 me
62 Multicenter, randomized,
double-blind, placebo-controlled trial conducted between
63 Azithromycin Treatment) study, a randomized,
double-blind, placebo-controlled trial conducted between
64 In a
double-blind, placebo-controlled trial conducted from 19
65 Fibrosis (ISIS), a multicenter, randomized,
double-blind, placebo-controlled trial conducted from Ap
66 Randomized,
double-blind, placebo-controlled trial conducted in 13 F
67 tal Asthma Reduction Trial was a randomized,
double-blind, placebo-controlled trial conducted in 3 ce
68 Multicenter, randomized,
double-blind, placebo-controlled trial conducted in 3 Sp
69 rdio was a phase 3, multicenter, randomized,
double-blind, placebo-controlled trial conducted in 720
70 In a randomized,
double-blind, placebo-controlled trial conducted in Euro
71 rican Region with Malaria) was a randomized,
double-blinded, placebo-controlled trial conducted in ma
72 This study was a randomized
double-blind placebo-controlled trial consisting of 100
73 KEEPS is a multicenter, randomized,
double-blinded, placebo-controlled trial,
designed to te
74 Several
double blind placebo controlled trials determined that C
75 Patients with NAFLD were randomised in a
double blind placebo-controlled trial [
DHA+EPA(n=51), pl
76 Part 1 consisted of a randomised,
double-blind, placebo-controlled trial done over 18 mont
77 Two international, randomized,
double-blind, placebo-controlled trials (
DUAL-1, DUAL-2)
78 A randomized,
double-blind, placebo-controlled trial (
Effects of Psych
79 In this first randomized,
double-blind, placebo-controlled trial,
enoxaparin (40 m
80 METHODS AND Randomized,
double-blinded, placebo-controlled trial enrolled 31 pat
81 Randomized,
double-blinded, placebo-controlled trial enrolled 31 pat
82 RELAX-AHF was an international,
double-blind, placebo-controlled trial,
enrolling patien
83 This randomized,
double-blind, placebo-controlled trial evaluated inhaled
84 This randomized,
double-blind, placebo-controlled trial evaluated ivacaft
85 Two identically designed, randomized,
double-blind, placebo-controlled trials evaluated the ef
86 NIZE was a phase 3, multicenter, randomized,
double-blind, placebo-controlled trial evaluating zircon
87 A randomized,
double-blind, placebo-controlled trial (
extend the safet
88 In a randomized,
double-blind, placebo-controlled trial,
five hundred and
89 The authors conducted a 16-week randomized
double-blind placebo-controlled trial for geriatric depr
90 Pooled data from randomized,
double-blind, placebo-controlled trials for the clinical
91 We performed a randomized, multicenter,
double-blind, placebo-controlled trial from 2007 to 2011
92 Following up these findings in a
double-blind placebo controlled trial in nondiabetic hea
93 We conducted a randomized
double-blind placebo-controlled trial in patients underg
94 We conducted a phase 2, randomized,
double-blind, placebo-controlled trial in 27 centers acr
95 We conducted a randomized,
double-blind, placebo-controlled trial in 69 hospitals i
96 We conducted a randomized,
double-blind, placebo-controlled trial in 740 schoolchil
97 We undertook this randomised,
double-blind, placebo-controlled trial in a general adul
98 We did this randomised,
double-blind, placebo-controlled trial in antenatal clin
99 Double-blind, placebo-controlled trial in HIV+ with CD4(
100 eworming, we conducted a cluster-randomized,
double-blind, placebo-controlled trial in Indonesia and
101 For this pragmatic randomised
double-blind, placebo-controlled trial in Khayelitsha, S
102 In a
double-blind, placebo-controlled trial in Niger, we rand
103 The T1DAL study is a phase 2,
double-blind, placebo-controlled trial in patients with
104 noma efficacy of vismodegib in a randomized,
double-blind, placebo-controlled trial in patients with
105 -of-concept study consisted of a randomised,
double-blind, placebo-controlled trial in patients with
106 a population-based, individually randomised,
double-blind, placebo-controlled trial in the Brong Ahaf
107 We undertook a phase 3, randomised,
double-blind, placebo-controlled trial in two children's
108 We did this randomised,
double-blind, placebo-controlled trial in two tertiary-c
109 We conducted a
double-blind, placebo-controlled trial in which 1537 pat
110 ineraux Antioxydants study was a randomized,
double-blind, placebo-controlled trial in which particip
111 We performed a randomized,
double-blind, placebo-controlled trial in which, after p
112 We reanalyzed 2
double-blind, placebo-controlled trials in unmedicated m
113 e III study were international, multicenter,
double-blind, placebo-controlled trials in which patient
114 Last, in a 4-mo,
double-blinded, placebo-controlled trial in older women
115 METHOD: This 6-week, randomized,
double-blind, placebo-controlled trial included patients
116 In a
double-blind placebo-controlled trial infants were rando
117 Randomized,
double-blinded, placebo-controlled trials investigating
118 This randomized,
double-blind, placebo-controlled trial involved a total
119 nt Sertraline Trial (CAST) was a randomized,
double-blind, placebo-controlled trial involving 201 pat
120 We conducted a randomized,
double-blind, placebo-controlled trial involving 27,564
121 We conducted a randomized,
double-blind, placebo-controlled trial involving 30,449
122 In a randomized,
double-blind, placebo-controlled trial involving 84,496
123 We performed a phase 2, multicenter,
double-blind, placebo-controlled trial involving 92 pati
124 We performed a randomized,
double-blind, placebo-controlled trial involving human i
125 We conducted a multicenter, randomized,
double-blind, placebo-controlled trial involving patient
126 We performed randomized,
double-blind, placebo-controlled trials involving adults
127 DESIGN, SETTING, AND PATIENTS: A randomized,
double-blind, placebo-controlled trial (
LateTIME) of the
128 analysis of pooled data from six randomized,
double-blind, placebo-controlled trials (
N = 1871) compa
129 This was a parallel,
double-blind placebo-controlled trial of 241 mother-infa
130 ew Guinea (PNG) participated in a randomised
double-blind placebo-controlled trial of blood- plus liv
131 elafibranor in an international, randomized,
double-blind placebo-controlled trial of patients with n
132 This was a multisite randomized
double-blind placebo-controlled trial of ultra-low-dose
133 A single-center, randomized,
double-blind, placebo-controlled trial of 153 patients u
134 We performed a
double-blind, placebo-controlled trial of 176 male infan
135 A prospective,
double-blind, placebo-controlled trial of 195 grass poll
136 010, a multicenter, prospective, randomized,
double-blind, placebo-controlled trial of 2 aggressive t
137 We performed a single-center,
double-blind, placebo-controlled trial of 2 separate coh
138 We did a randomised, parallel group,
double-blind, placebo-controlled trial of 20 mg memantin
139 We performed a prospective,
double-blind, placebo-controlled trial of 449 consecutiv
140 AND PARTICIPANTS: A multicenter, randomized,
double-blind, placebo-controlled trial of 4494 patients
141 ebo in 30 cases), we performed a randomized,
double-blind, placebo-controlled trial of 5 days of 80 m
142 e Physicians' Health Study II, a randomized,
double-blind, placebo-controlled trial of a common daily
143 At a single site, we did a randomised,
double-blind, placebo-controlled trial of a monovalent i
144 We conducted a phase 3, randomized,
double-blind, placebo-controlled trial of a monthly vagi
145 An ongoing phase 2, randomised,
double-blind, placebo-controlled trial of a TDV is being
146 We performed a prospective, randomized,
double-blind, placebo-controlled trial of adults with eo
147 t; and the recent completion of the largest,
double-blind, placebo-controlled trial of AIH treatment
148 We conducted a randomized,
double-blind, placebo-controlled trial of amitriptyline
149 Here we report on a randomized,
double-blind, placebo-controlled trial of an oral synbio
150 We performed a randomized,
double-blind, placebo-controlled trial of anastrozole in
151 We did a randomised,
double-blind, placebo-controlled trial of canakinumab in
152 We conducted a multicenter, randomized,
double-blind, placebo-controlled trial of caspofungin as
153 We conducted a 7 +/- 0.5-mo randomized,
double-blind, placebo-controlled trial of CLA in 62 prep
154 We conducted a randomized, multisite,
double-blind, placebo-controlled trial of daily 1760 mcg
155 We performed a randomized,
double-blind, placebo-controlled trial of DAR-0100A (15
156 ARTICIPANTS: Twelve-month, randomized (1:1),
double-blind, placebo-controlled trial of erythromycin i
157 NG, AND PATIENTS: A multicenter, randomized,
double-blind, placebo-controlled trial of flexible-dose
158 ervals in a substudy of iPrEx, a randomized,
double-blind, placebo-controlled trial of FTC/TDF PrEP.
159 D Assessment (ViDA) Study was a randomised,
double-blind, placebo-controlled trial of healthy volunt
160 riori substudy of a multicenter, randomized,
double-blind, placebo-controlled trial of hydrocortisone
161 We did an individually randomised,
double-blind, placebo-controlled trial of infants born i
162 en in Crisis (MAGiC) study was a randomized,
double-blind, placebo-controlled trial of intravenous ma
163 We conducted a randomized,
double-blind, placebo-controlled trial of ivabradine, ad
164 A 10-week, randomized,
double-blind, placebo-controlled trial of lamotrigine wa
165 were also eligible for a nested, randomised,
double-blind, placebo-controlled trial of MVA-BN-Filo.
166 In this first randomized,
double-blind, placebo-controlled trial of omalizumab in
167 r et al report the first 1-year, randomized,
double-blind, placebo-controlled trial of oral iron chel
168 esistance Intervention After Stroke trial, a
double-blind, placebo-controlled trial of pioglitazone f
169 Subjects in this prospective, randomized,
double-blind, placebo-controlled trial of post-menopausa
170 We conducted a randomized,
double-blind, placebo-controlled trial of pregabalin in
171 rolled in a 3-month multicenter, randomized,
double-blind, placebo-controlled trial of R788.
172 We performed a 2-year multicentre,
double-blind, placebo-controlled trial of subcutaneous i
173 antagonist, on albuminuria in a randomized,
double-blind, placebo-controlled trial of subjects with
174 these nutrients, we conducted a randomized,
double-blind, placebo-controlled trial of supplementatio
175 SETTING, AND PATIENTS: A phase 2 randomized
double-blind, placebo-controlled trial of symptomatic pa
176 ects participating in a phase I, randomized,
double-blind, placebo-controlled trial of the anti-IL-17
177 participants in the BLESS trial, a 12-month,
double-blind, placebo-controlled trial of twice-daily er
178 VDAART), a well-conducted large, randomized,
double-blind, placebo-controlled trial of vitamin D supp
179 We did a randomised,
double-blind, placebo-controlled trial of vitamin D3 sup
180 d in the Women's Health Study, a randomized,
double-blind, placebo-controlled trial of vitamin E (600
181 (TRA 2 degrees P-TIMI 50) was a randomized,
double-blind, placebo-controlled trial of vorapaxar in 2
182 s (TRA2 degrees P-TIMI 50) was a randomized,
double-blind, placebo-controlled trial of vorapaxar in 2
183 hemic Events-TIMI 50 trial was a randomized,
double-blind, placebo-controlled trial of vorapaxar in p
184 arction 50) was a multinational, randomized,
double-blind, placebo-controlled trial of vorapaxar in s
185 0 (TRA2 degrees P-TIMI 50) was a randomized,
double-blind, placebo-controlled trial of vorapaxar in s
186 were pooled from two phase III, randomized,
double-blind, placebo-controlled trials of IFN-gamma-1b
187 This review analyzed randomized
double-blind, placebo-controlled trials of molecularly t
188 nth follow-up in the two largest randomized,
double-blind, placebo-controlled trials of naltrexone in
189 m inception to Jan 31, 2016, for randomised,
double-blind, placebo-controlled trials of second-genera
190 We conducted two multicenter, randomized,
double-blind, placebo-controlled trials of subcutaneous
191 Data from randomized,
double-blind, placebo-controlled trials of Timothy grass
192 We conducted three phase 3, randomized,
double-blind, placebo-controlled trials of tofacitinib t
193 We conducted two integrated randomized,
double-blind, placebo-controlled trials of vedolizumab i
194 We report findings from a 12-week randomized
double-blinded placebo-controlled trial of methylphenida
195 thogenesis of HA, we performed a randomized,
double-blinded, placebo-controlled trial of human recomb
196 these questions, we performed a randomized,
double-blinded, placebo-controlled trial of recombinant
197 rom women who were enrolled in a randomized,
double-blinded, placebo-controlled trial of vitamin D su
198 vs placebo has been clearly demonstrated, a
double-blind placebo-controlled trial on the effect of l
199 In a multicenter,
double-blind, placebo-controlled trial,
participants pre
200 In this phase III,
double-blind, placebo-controlled trial,
patients with ch
201 In this single-centre, randomised,
double-blind, placebo-controlled trial,
patients with mo
202 In this randomized,
double-blind, placebo-controlled trial,
patients with on
203 Patients and Methods In this
double-blinded, placebo-controlled trial,
patients with
204 DESIGN, SETTING, AND PATIENTS: Randomized,
double-blind, placebo-controlled trial performed at 10 H
205 ith Sustained Tocolysis in Early Labor) is a
double-blind, placebo-controlled trial performed in 11 p
206 AND PARTICIPANTS: A large-scale, randomized,
double-blind, placebo controlled trial (
Physicians" Heal
207 magnetic resonance imaging to a randomized,
double-blind, placebo-controlled trial (
RCT) of antidepr
208 This randomized,
double-blind, placebo-controlled trial recruited patient
209 This PreSERVE-AMI (Phase 2, randomized,
double-blind, placebo-controlled trial)
represents the l
210 se II, multicenter, prospective, randomized,
double-blind, placebo-controlled trial stratified by sit
211 In two identically designed, phase 3,
double-blind, placebo-controlled trials (
TARGET 1 and TA
212 hysicians' Health Study II was a randomized,
double-blind, placebo-controlled trial testing multivita
213 ) study, a phase 3, multicenter, randomized,
double-blind, placebo-controlled trial that enrolled 301
214 proof-of-concept study (POC) was an 8-week,
double-blind, placebo-controlled trial that evaluated LY
215 The authors provide results from a
double-blind, placebo-controlled trial that evaluated th
216 SOLID-TIMI 52 was a multinational,
double-blind, placebo-controlled trial that randomized 1
217 Vitamin D Assessment Study is a randomized,
double-blind, placebo-controlled trial that recruited pa
218 A randomized,
double-blind, placebo-controlled trial that used a 2 x 2
219 There were 7
double-blind, placebo-controlled trials that were rated
220 For maintenance, 6
double-blind, placebo-controlled trials that were rated
221 In a randomized,
double-blind, placebo-controlled trial (
the Dietary Inte
222 AND PATIENTS: A randomized, 2 x 2 factorial,
double-blind, placebo-controlled trial,
Timing In Myocar
223 The authors conducted a
double-blind placebo-controlled trial to assess whether
224 alyzed data from 1092 patients enrolled in a
double-blind placebo-controlled trial to evaluate the ef
225 a, the authors conducted a 6-week randomized
double-blind placebo-controlled trial to investigate the
226 We conducted a
double-blind, placebo-controlled trial to assess the eff
227 We performed a randomized,
double-blind, placebo-controlled trial to determine whet
228 We conducted a randomized,
double-blind, placebo-controlled trial to evaluate ivaca
229 We performed a randomized,
double-blind, placebo-controlled trial to evaluate the e
230 We conducted a
double-blind, placebo-controlled trial to evaluate the e
231 We performed a phase IIb, randomized,
double-blind, placebo-controlled trial to evaluate the e
232 ith adalimumab 2 (ULTRA 2) was a randomized,
double-blind, placebo-controlled trial to evaluate the e
233 We performed a
double-blind, placebo-controlled trial to evaluate the e
234 We conducted a
double-blind, placebo-controlled trial to evaluate the i
235 30 mo of age) were enrolled in a randomized,
double-blind, placebo-controlled trial to receive 2 time
236 This is an ongoing randomized,
double-blinded, placebo-controlled trial to evaluate the
237 REMOVAL was a
double-blind, placebo-controlled trial undertaken at 23
238 ObaapaVitA was a cluster-randomised,
double-blind, placebo-controlled trial undertaken in sev
239 In this
double-blind, placebo-controlled trial,
undertaken acros
240 Phase 2 randomized, multicenter,
double-blind, placebo-controlled trial using a sequentia
241 A prospective multi-centre randomised
double-blind placebo-controlled trial was performed in p
242 This randomized,
double-blind, placebo-controlled trial was carried out i
243 A randomized
double-blind, placebo-controlled trial was conducted in
244 A randomized,
double-blind, placebo-controlled trial was conducted in
245 n October 2007 and April 2008, a randomized,
double-blind, placebo-controlled trial was conducted in
246 A randomized,
double-blind, placebo-controlled trial was conducted.
247 This phase 2, randomised,
double-blind, placebo-controlled trial was done in 72 ba
248 A randomized,
double-blind, placebo-controlled trial was performed in
249 A phase 3, randomized,
double-blind, placebo-controlled trial was performed to
250 The aim of this randomized,
double-blind, placebo-controlled trial was to test the e
251 This phase 3,
double-blind, placebo-controlled trial was undertaken at
252 This multicentre, randomised,
double-blind, placebo-controlled trial was undertaken at
253 In a randomized,
double-blind, placebo-controlled trial we administered 5
254 In our randomised,
double-blind, placebo-controlled trial we enrolled adult
255 In this 44-week, randomised,
double-blind, placebo-controlled trial we enrolled child
256 In this randomised,
double-blind, placebo-controlled trial we recruited part
257 In this post-hoc analysis of a randomized,
double blind, placebo controlled trial,
we measured the
258 In this international, phase 3, randomized,
double-blind, placebo-controlled trial,
we assigned 1088
259 In this randomized,
double-blind, placebo-controlled trial,
we assigned 2120
260 In this randomized,
double-blind, placebo-controlled trial,
we assigned pati
261 In this multicenter, randomized,
double-blind, placebo-controlled trial,
we assigned prev
262 In a multicenter, randomized,
double-blind, placebo-controlled trial,
we compared alef
263 In a 50-week,
double-blind, placebo-controlled trial,
we compared meth
264 In this phase 2, randomized,
double-blind, placebo-controlled trial,
we compared subc
265 In this single-center, randomized,
double-blind, placebo-controlled trial,
we enrolled 120
266 In this randomised,
double-blind, placebo-controlled trial,
we enrolled 2507
267 In our
double-blind, placebo-controlled trial,
we enrolled adul
268 In a prospective, randomized,
double-blind, placebo-controlled trial,
we enrolled pati
269 In this randomized,
double-blind, placebo-controlled trial,
we investigated
270 In a phase 2,
double-blind, placebo-controlled trial,
we randomized 63
271 In this randomised,
double-blind, placebo-controlled trial,
we randomly allo
272 In this
double-blind, placebo-controlled trial,
we randomly assi
273 In our initial
double-blind, placebo-controlled trial,
we randomly assi
274 In this
double-blind, placebo-controlled trial,
we randomly assi
275 In this randomized,
double-blind, placebo-controlled trial,
we randomly assi
276 In a
double-blind, placebo-controlled trial,
we randomly assi
277 In this multicenter,
double-blind, placebo-controlled trial,
we randomly assi
278 In our phase 2,
double-blind, placebo-controlled trial,
we randomly assi
279 In this
double-blind, placebo-controlled trial,
we randomly assi
280 In this
double-blind, placebo-controlled trial,
we randomly assi
281 In this
double-blind, placebo-controlled trial,
we randomly assi
282 In this phase III, multicenter,
double-blind, placebo-controlled trial,
we randomly assi
283 In this
double-blind, placebo-controlled trial,
we randomly assi
284 In this multicenter,
double-blind, placebo-controlled trial,
we randomly assi
285 In this phase 3,
double-blind, placebo-controlled trial,
we recruited pat
286 In this randomised,
double-blind, placebo-controlled trial,
we recruited pat
287 In our phase 3,
double-blind, placebo-controlled trial,
we stratified 11
288 In a preregistered, randomized,
double-blind, placebo-controlled trial,
we tested the ef
289 In this randomized,
double-blind, placebo-controlled trial,
we treated adult
290 In a pilot prospective, randomized,
double-blinded, placebo-controlled trial,
we studied whe
291 Two parallel,
double-blind, placebo-controlled trials were conducted w
292 Purpose To determine, in a multicenter
double-blinded placebo-controlled trial,
whether maximal
293 We performed a randomized,
double-blind, placebo-controlled trial with a 12-week ba
294 NG, AND PATIENTS: A prospective, randomized,
double-blind, placebo-controlled trial with a dose-escal
295 We undertook this randomised,
double-blind, placebo-controlled trial with four paralle
296 We now report that in a
double-blind, placebo-controlled trial with healthy part
297 This was a
double-blind, placebo-controlled trial with subjects ran
298 moprevention (VAKCC) trial was a randomized,
double-blinded, placebo-controlled trial with patients f
299 In this multicentre, block-randomised,
double-blind, placebo-controlled trial,
women aged 18-40
300 In this Phase 4, multi-center,
double-blind, placebo-controlled trial,
young adults (18